Role of Tyrosine Kinase Lyn and Cleaved Form by Caspases in Psoriasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

170 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-07-31

Study Completion Date

2016-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Psoriasis is a chronic autoimmune disorder of the skin. In this disease, the inflammatory caspases, cysteine proteases involved in the processing of many proteins, are activated. Transgenic mice expressing the cleaved form of caspases by Lyn, a tyrosine kinase Src family, develop an inflammatory syndrome with the characteristics of human psoriasis.

To clarify the relationship between the cleaved form of Lyn by caspases and psoriasis, the investigators intend to develop a clinical study to analyze the expression, cleavage and activity of Lyn and the activation of caspases from skin biopsies of patients with this disease.

This study will be conducted on a cohort of patients with different forms of psoriasis (plaque, pustular and erythrodermic) and atopic dermatitis, another skin disorder associated with chronic inflammation. Thus, the investigators will evaluate the expression and activity of Lyn from skin lesion (L) and non-lesional (NL) from the same patient in parallel with the level of caspase activation and apoptotic inflammatory.

Thus, the investigators will verify that the cleavage by caspases of Lyn is associated specifically with psoriasis, as the investigators believe, or more generally to the skin inflammation. The investigators work would then define the cleavage by caspases of Lyn as a new potential marker of human psoriasis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of Reverse Transcriptase Inhibitors in the Treatment of Psoriasis

NCT04274595

Psoriasis

COMPLETED NA

Immune Infiltrate Analysis of Psoriasis Skin During Therapy With Anti-interleukin 23 (IL-23)

NCT06792487

Psoriasis

RECRUITING

Efficacy Study of Trichuris Suis Ova to Treat Chronic Plaque Psoriasis

NCT01948271

Psoriasis

TERMINATED PHASE1

To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris

NCT00050648

Psoriasis

COMPLETED PHASE1/PHASE2

Open Clinical Study, Comparing Non-inferiority of Chronic Plaque Psoriasis

NCT01279629

Plaque Psoriasis

SUSPENDED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis Atopic Dermatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

chronic plaque psoriasis

3 biopsies: 2 lesional and 1 non-lesional

Group Type OTHER

3 Biopsies

Intervention Type OTHER

3 biopsies: 2 lesional and 1 non-lesional

pustular psoriasis

3 biopsies: 2 lesional and 1 non-lesional

Group Type OTHER

3 Biopsies

Intervention Type OTHER

3 biopsies: 2 lesional and 1 non-lesional

erythrodermic psoriasis

3 biopsies: 2 lesional and 1 non-lesional

Group Type OTHER

3 Biopsies

Intervention Type OTHER

3 biopsies: 2 lesional and 1 non-lesional

atopic dermatitis

2 biopsies: 1 lesional and 1 non-lesional

Group Type OTHER

2 biopsies

Intervention Type OTHER

healthy patients

1 biopsy of healthy skin.

Group Type OTHER

biopsy

Intervention Type OTHER

1 biopsy ok healthy skin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

3 Biopsies

3 biopsies: 2 lesional and 1 non-lesional

Intervention Type OTHER

2 biopsies

Intervention Type OTHER

biopsy

1 biopsy ok healthy skin

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

1 lesional and 1 non-lesional

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Psoriasis arms:

* Plaque psoriasis and erythrodermic more than 10% of body surface area.
* Pustular psoriasis of at least 1% of body surface.

* Atopic dermatitis arm:Patients with atopic dermatitis has been identified and inflammatory lesions on the skin.
* Healthy arm:People not suffering from any skin disease

Exclusion Criteria

* Systemic treatment of psoriasis for at least 4 weeks and / or local treatment for at least 2 weeks at the time of study entry.
* Patient with significant infection and / or immunocompromised.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes